Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

R-3750 in Patients With Crohn's Disease

26. august 2026 opdateret af: Rise Therapeutics LLC

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Clinical Activity, and Pharmacodynamic Effects of R-3750 in Patients With Crohn's Disease

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, clinical activity, and pharmacodynamic effects of R-3750 in adults with active Crohn's disease. Approximately 40 participants will be randomized 1:1 to receive R-3750 or matching placebo orally once daily for 12 weeks. Participants will be followed for safety, clinical response, and durability of response through approximately Day 168. Assessments will include adverse events, Crohn's disease activity, endoscopic response, patient-reported outcomes, inflammatory biomarkers, microbiome composition, and pharmacodynamic measures.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a multicenter, randomized, double-blind, placebo-controlled Phase 1 study designed to evaluate the safety, tolerability, clinical activity, and pharmacodynamic effects of R-3750 in adults with active Crohn's disease.

Approximately 40 participants will be randomized in a 1:1 ratio to receive either R-3750 at a dose of 9E10 colony-forming units (CFU) per day or matching placebo administered orally once daily for 12 weeks. Participants, investigators, study site personnel involved in outcome assessments, and Sponsor personnel involved in study conduct and assessment will remain blinded to treatment assignment.

Eligible participants will be adults 18 to 80 years of age with active Crohn's disease, defined by a Harvey-Bradshaw Index (HBI) score of 5 to 15 and objective evidence of active inflammatory disease based on C-reactive protein (CRP), fecal calprotectin, biopsy-verified inflammation, and/or endoscopic assessment.

The study consists of a screening period, a 12-week treatment period from Day 1 through Day 84, and a safety follow-up period through approximately Day 168.

Safety and tolerability will be evaluated through the assessment of adverse events and serious adverse events, clinical laboratory parameters, vital signs, and physical examinations. Clinical activity will be evaluated using measures including the Crohn's Disease Activity Index (CDAI) and HBI. Additional assessments will evaluate clinical remission, endoscopic response, patient-reported outcomes, inflammatory biomarkers, microbiome composition, immune phenotypes, metabolomic profiles, and other pharmacodynamic measures.

An independent Medical Monitor will review available safety data on an ongoing basis, and a Data Monitoring Committee (DMC) will review cumulative safety data during the study.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Christian F Freguia, PhD
  • Telefonnummer: 215-923-1818

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Age 18 to 80 years, inclusive, at the time of informed consent.
  • Able and willing to provide written informed consent and comply with study procedures and study visits.
  • Documented diagnosis of Crohn's disease with symptoms/onset of disease at least 3 months prior to Screening.
  • Active Crohn's disease defined by Harvey-Bradshaw Index (HBI) score between 5 and 15 at Screening.
  • Evidence of active inflammatory disease, defined by at least one of the following: CRP ≥5 mg/L, fecal calprotectin ≥50 µg/g, biopsy-verified inflammation, or endoscopic evidence of active inflammation.
  • Women of childbearing potential must have a negative pregnancy test at Screening and before dosing and agree to use highly effective contraception during the study and for at least 3 months after the last dose.
  • Men with partners of childbearing potential must agree to use contraception according to institutional requirements during the study and for at least 3 months after the last dose.

Exclusion Criteria:

  • Crohn's disease in clinical remission, including HBI <5 or CDAI <150 at Screening.
  • Severe Crohn's disease requiring urgent escalation of therapy, hospitalization, or surgery in the opinion of the Investigator.
  • Imminent risk of scheduled intestinal surgery, including clinically significant stenosis, strictures, internal fistula, abscess, or obstructive complications.
  • History of partial or incomplete bowel obstruction within 6 months prior to Screening; current stoma, ileostomy, colostomy, or anticipated need for ostomy during the study; diagnosis of short bowel syndrome or clinically significant malabsorptive condition; uncontrolled chronic diarrhea due to a condition other than Crohn's disease; or bowel resection within 3 months prior to Screening.

Subjects with prior bowel resection may be eligible if, in the opinion of the Investigator and Sponsor, the remaining bowel anatomy is adequate for study participation and interpretation of study endpoints.

  • History (past 6 months) or current Clostridioides difficile infection, clinically significant enteric infection, other active infection or chronic infection requiring ongoing antimicrobial treatment.
  • Treatment with antibiotics within 2 weeks prior to Day 1 or expected during the study period.
  • Use of biologic, targeted synthetic, or systemic immunomodulatory/immunosuppressive therapy for Crohn's disease within the 4 weeks washout period prior to Day 1, unless specifically permitted. Stable doses of aminosalicylates, budesonide, or low-dose systemic corticosteroids are permitted if stable for at least 2 weeks prior to Day 1 and expected to remain stable during the treatment period. Low-dose systemic corticosteroids are defined as prednisone ≤20 mg/day or equivalent.
  • Use of probiotics or live biotherapeutic products within 2 weeks prior to Day 1.
  • Severe comorbidities, including uncontrolled diabetes, clinically significant cardiopulmonary failure, severe liver disease, severe renal disease, or other clinically significant condition that would place the subject at risk or confound study interpretation.
  • Abnormal hepatic function, including ALT or ALP >2.5 × ULN, liver cirrhosis, portal hypertension, or clinically significant active liver disease.
  • Abnormal renal function, including cystatin C >ULN or other clinically significant renal abnormality.
  • Known active blood-borne infection, including HIV, active hepatitis A, B, or C infection, or tuberculosis.
  • History of malignancy within 5 years prior to Day 1, except adequately treated non-metastatic basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
  • Pregnant, breastfeeding, or planning to become pregnant during the study. Clinically significant mental disorder, substance use disorder, alcohol or drug addiction that may interfere with participation or compliance.
  • Participation in another interventional clinical trial within 30 days prior to Day 1 or simultaneous participation in another interventional clinical trial.
  • Any significant disease, disorder, laboratory abnormality, or circumstance that, in the opinion of the Investigator, may put the subject at risk, affect study results, or interfere with study participation.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm 1: R-3750, 9E10 CFU/day orally once daily for 12 weeks
Participants randomized to the experimental arm will receive R-3750 at a dose of 9E10 colony-forming units (CFU) per day, administered orally once daily from Day 1 through Day 84 (12 weeks).
R-3750 DP is a live biotherapeutic product consisting of Lactococcus lactis engineered to express Surface Layer Protein A (SlpA), formulated in enteric-coated capsules for oral administration. Participants randomized to R-3750 will receive 9E10 colony-forming units (CFU) per day orally once daily from Day 1 through Day 84.
Placebo komparator: Arm 2: Matching placebo orally once daily for 12 weeks
Participants randomized to the placebo comparator arm will receive matching placebo administered orally once daily from Day 1 through Day 84 (12 weeks).
Matching placebo will be administered orally once daily from Day 1 through Day 84.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Adverse Events.
Tidsramme: From first dose through Day 168 end of study
Number of participants experiencing one or more treatment-emergent adverse events following administration of R-3750 or placebo.
From first dose through Day 168 end of study

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with serious adverse advents
Tidsramme: From first dose through Day 168 end of study
Number of particpants experiencing one or more serious adverse events following administration of R-3750 or placebo.
From first dose through Day 168 end of study

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants with Clinically Significant Abnormal Clinical Laboratory Results
Tidsramme: From baseline through Day 168 end of study
Number of participants with clinically significant abnormalities in protocol-specified hematology and clinical chemistry laboratory assessments.
From baseline through Day 168 end of study
Number of Participants with Clinically Significant Abnormal Vital Signs
Tidsramme: From baseline through Day 168 end of study
Number of participants with clinically significant abnormalities in protocol-specified vital sign assessments.
From baseline through Day 168 end of study
Number of Participants with Clinically Significant Abnormal Physical Examination Findings
Tidsramme: From baseline through Day 168 end of study
Number of participants with new or worsened clinically significant physical examination findings after baseline.
From baseline through Day 168 end of study

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

31. december 2028

Studieafslutning (Anslået)

31. marts 2029

Datoer for studieregistrering

Først indsendt

18. august 2026

Først indsendt, der opfyldte QC-kriterier

26. august 2026

Først opslået (Faktiske)

28. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner